Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis.

Nao TokaiShuzo YoshidaTakuya KotaniAyaka YoshikawaYuko KimuraYouhei FujikiYoko MatsumuraTohru TakeuchiShigeki MakinoShigeki Arawaka

Published in: PloS one (2018)

Our findings suggest that the ratios of the serum MMP-3 levels at baseline to those at 12 weeks could be used to predict remission in RA patients who are administered iguratimod as an add-on to bDMARDs.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
rheumatoid arthritis
disease activity
peritoneal dialysis
prognostic factors
stem cells
systemic sclerosis
interstitial lung disease